13F GuideFiling Basics
What is SEC Form 13F? Ultimate Guide to Institutional Equity Filings
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
AlphaSMO Research GuideRead Guide
CIK: 0000078003
Total reported value
$170.4M
$170.4M
23 檔
1441.0%
During the Q4 2024 filing period, Pfizer Inc (CIK: 0000078003) submitted its Form 13F report to the U.S. SEC, disclosing a tracked public equity portfolio valued at $170.4M across 23 reported positions.
During Q4 2024, Pfizer Inc's portfolio maintained high stability with no major positional turnover, reflecting a continuous long-term holding approach.
| # | Ticker | Issuer | Asset Subclass | Weight | Weight Change | Shares Change | 4Q Trend |
|---|---|---|---|---|---|---|---|
| 1 | HLN | Haleon Plc-adr | Stock-Healthcare | 72.59% | — | — | |
| 2 | BNTX | Biontech Se-adr | Stock-Other | 16.08% | — | — | |
| 3 | ARVN | Arvinas Inc | Stock-Other | 2.56% | +1.61% | — | |
| 4 | ALLO | Allogene Therapeutics Inc | Stock-Other | 1.81% | +6.70% | — | |
| 5 | ORIC | Oric Pharmaceuticals Inc | Stock-Other | 1.67% | -22.05% | — | |
| 6 | TRML | Tourmaline Bio Inc | Stock-Other | 1.00% | — | — | |
| 7 | WVE | Wave Life Sciences Ltd. | Stock-Other | 0.89% | +1.42% | — | |
| 8 | BHVN | Biohaven Ltd. | Stock-Other | 0.73% | +2.93% | — | |
| 9 | AKRO | Akero Therapeutics Inc | Stock-Other | 0.60% | — | — | |
| 10 | PYXS | Pyxis Oncology Inc | Stock-Other | 0.42% | +7.57% | — | |
| 11 | CRDF | Cardiff Oncology Inc | Stock-Other | 0.40% | +0.20% | — | |
| 12 | CRBU | Caribou Biosciences Inc | Stock-Other | 0.29% | +1.13% | — | |
| 13 | ✓ | Zura Bio LTD | Stock-Other | 0.29% | -5.36% | — | |
| 14 | CELC | Celcuity Inc | Stock-Other | 0.18% | +4.22% | — | |
| 15 | EPIEUR | Essa Pharma Inc | Stock-Other | 0.12% | — | — | |
| 16 | ZNTL | Zentalis Pharmaceuticals Inc | Stock-Other | 0.11% | +1.42% | — | |
| 17 | SPRO | Spero Therapeutics Inc | Stock-Other | 0.09% | +0.82% | — | |
| 18 | NXTCEUR | Nextcure Inc | Stock-Other | 0.07% | — | — | |
| 19 | ANTX | An2 Therapeutics Inc | Stock-Other | 0.04% | — | — | |
| 20 | QTTB | Q32 Bio Inc | Stock-Other | 0.04% | -0.31% | EXIT | |
| 21 | BOLT1EUR | Bolt Biotherapeutics Inc | Stock-Other | 0.01% | — | — | |
| 22 | DNA | Ginkgo Bioworks Holdings Inc | Stock-Other | — | +0.01% | — | |
| 23 | SENS1GBP | Senseonics Holdings Inc | Stock-Other | — | — | — |
According to official SEC Form 13F filings, Pfizer Inc reported a total U.S. public equity portfolio value of $170.4M across 23 disclosed positions in Q4 2024.
During Q4 2024, Pfizer Inc's top holdings by market value included HLN (72.6%)、BNTX (16.1%)、ARVN (2.6%). The largest single position, HLN, represented 72.6% of total portfolio value.
Expert Analysis & Guides for Tracking Wall Street Smart Money Movements
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
In terms of portfolio concentration, the top 5 core holdings (including HLN, BNTX, ARVN) accounted for 1441.0% of total reported equity market value during Q4 2024.
In Q4 2024, Pfizer Inc made 0 total portfolio adjustments, initiating 0 new buys, adding to 0 positions, trimming 0 holdings, and fully liquidating 0 stocks.
All holding records on this page are fetched directly from the U.S. Securities and Exchange Commission (SEC) EDGAR system (Form 13F-HR). AlphaSMO parses CUSIP identifiers and formats data into Schema.org-compliant datasets.
Understand SEC Form 4 insider disclosures for corporate officers, directors, and 10% owners to track executive transactions.
Understand Rule 144 restricted stock sale notices to spot planned insider liquidations before market sell pressure arrives.
Explore the 5% beneficial ownership threshold, 13D vs 13G filing differences, and recent SEC accelerated deadline rules.
Best practices for analyzing 13F quarterly changes without getting misled by stock splits, options, or market valuation drift.
Learn how AlphaSMO's flagship signal detects high-conviction stocks where 13F hedge funds and corporate insiders buy at the same time.